FusionPharm, Inc. (FSPM) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerFusionPharm, Inc. (FSPM) trades at $0.0001. FusionPharm, Inc. specializes in developing and manufacturing cultivation containers, primarily the PharmPod system, for indoor plant cultivation. The company caters to businesses, universities, and individuals in the United States. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for FSPM: FSPM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
FusionPharm, Inc. (FSPM) Healthcare & Pipeline Overview
FusionPharm, Inc. focuses on cultivation container systems, specifically PharmPods, catering to the indoor plant cultivation market in the United States. With a small team, the company targets businesses, universities, and individuals, offering controlled environment solutions for various plant types, operating within the pharmaceutical retailers sector.
What Is the Investment Thesis for FSPM?
FusionPharm, Inc. presents a high-risk, high-reward investment profile due to its focus on the niche market of cultivation containers. The company's small market capitalization and negative profit margin of -110.7% indicate significant financial challenges. A beta of 30.49 suggests extreme volatility relative to the market. Growth catalysts depend on expanding market reach and product adoption within the indoor plant cultivation sector. The investment thesis hinges on FusionPharm's ability to innovate and capture a larger share of this specialized market, while mitigating risks associated with limited financial resources and intense competition. Investors should closely monitor the company's ability to improve profitability and secure additional funding.
Based on FMP financials and quantitative analysis
FSPM Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited resources.
- Negative profit margin of -110.7% reflects significant operational challenges and potential financial instability.
- Gross margin of 20.4% suggests some ability to generate revenue above the cost of goods sold, but needs improvement.
- Negative Free Cash Flow (FCF) of $-0.00B indicates the company is not generating positive cash flow from its operations.
- Beta of 30.49 indicates extremely high volatility compared to the overall market, suggesting a high-risk investment.
Who Are FSPM's Competitors?
FSPM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are FSPM's Key Strengths?
Specialized cultivation container systems.
- Focus on the indoor plant cultivation market.
- Established brand name (PharmPod).
What Are FSPM's Weaknesses?
Limited financial resources.
- Negative profit margin.
- Small market capitalization.
What Are the Key Risks for FSPM?
Limited financial resources may hinder growth and expansion.
- Intense competition in the cultivation container market could erode market share.
- Regulatory changes affecting indoor plant cultivation could impact operations.
- Negative profit margin indicates financial instability.
- Dependence on a niche market makes the company vulnerable to changes in demand.
What Are FSPM's Competitive Advantages?
- Specialized PharmPod cultivation container design.
- Focus on the niche market of indoor plant cultivation.
- Established brand recognition within the cultivation container market.
What Does FSPM Do?
Incorporated in 1998 and rebranded as FusionPharm, Inc. in 2011, the company designs, manufactures, and sells cultivation containers under the PharmPod brand. These PharmPods are designed for indoor plant cultivation, offering a controlled environment for growing various plants. FusionPharm caters to a diverse clientele, including businesses, universities, and individual cultivators across the United States. The company's focus is on providing specialized container systems that optimize plant growth in indoor settings. The PharmPod system aims to provide a controlled environment, addressing the specific needs of indoor cultivation. FusionPharm's evolution reflects a strategic shift towards specialized cultivation solutions, focusing on the indoor plant cultivation market. Based in Commerce City, Colorado, FusionPharm operates with a small team, emphasizing innovation and targeted solutions for its niche market. The company's offerings are tailored to meet the evolving demands of indoor agriculture and research.
What Products and Services Does FSPM Offer?
- Develops and manufactures PharmPod cultivation containers.
- Sells PharmPods to businesses, universities, and individuals.
- Offers cultivation container systems for indoor plant cultivation.
- Provides controlled environment solutions for plant growth.
- Caters to the indoor plant cultivation market in the United States.
- Specializes in cultivation solutions for various plant types.
How Does FSPM Make Money?
- Generates revenue through the sale of PharmPod cultivation containers.
- Targets businesses, universities, and individuals in the United States.
- Offers specialized cultivation solutions for indoor plant growth.
What Industry Does FSPM Operate In?
FusionPharm, Inc. operates within the pharmaceutical retailers sector, focusing on cultivation containers for indoor plant growth. The market for controlled environment agriculture (CEA) is expanding, driven by increasing demand for locally sourced and high-quality produce. Competition includes companies offering similar cultivation solutions and broader agricultural technology providers. FusionPharm's success depends on its ability to differentiate its PharmPod system and capture market share in this evolving landscape. The industry is influenced by technological advancements, regulatory changes, and consumer preferences for sustainable agriculture practices.
Who Are FSPM's Key Customers?
- Businesses involved in indoor plant cultivation.
- Universities conducting plant science research.
- Individuals interested in cultivating plants indoors.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
FusionPharm, Inc. operates in the Healthcare sector. It is headquartered in Commerce City, US. The company is led by CEO William J. Sears. FSPM has traded publicly since 1993.
FSPM Financials
FSPM Latest News
No recent news available for FSPM.
FSPM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for FSPM.
Price Targets
Wall Street price target analysis for FSPM.
FSPM MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for FSPM; grades run from A+ (80-100) to F (below 30).
FSPM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that FusionPharm, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is often associated with speculative investments and requires a high degree of due diligence.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in FSPM.
- Low liquidity can make it difficult to buy or sell shares.
- The OTC Other tier is associated with higher risk of fraud and manipulation.
- Small market capitalization increases volatility.
- Negative profit margin indicates financial instability.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Determine the company's ownership structure and any potential conflicts of interest.
- Consult with a financial advisor to assess the risks and potential rewards.
- Research the company's history and any past legal or regulatory issues.
- Company has been in operation since 1998.
- Focus on a specific niche market (cultivation containers).
- Offers a tangible product (PharmPod system).
FSPM Healthcare Stock FAQ
What do analysts say about FSPM stock?
As of 2026-03-16, there is no available analyst coverage or consensus for FusionPharm, Inc. (FSPM) due to its micro-cap status and listing on the OTC Other tier.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available due to OTC Other tier listing.
- Financial data may not be fully reliable due to lack of regulatory oversight.